SS Innovations International Inc. (NASDAQ: SSII) reported record first-quarter 2026 revenue of $11.1 million, a 116.8% increase year over year, driven by the accelerating adoption of its SSi Mantra surgical robotic system. The company's installed base reached 194 systems across 11 countries, with nearly 9,750 cumulative robotic procedures completed during the quarter. These results highlight the company's expanding footprint in international markets, particularly in emerging economies where surgical robotics are less prevalent.
The company's growth is underpinned by recent regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines, which have opened new markets for the SSi Mantra system. Additionally, SS Innovations recently completed the world's longest-distance robotic cardiac telesurgery, demonstrating the platform's remote surgery capabilities. This achievement has significant implications for expanding access to specialized surgical care in underserved regions, as telesurgery allows surgeons to operate on patients thousands of miles away.
As of June 22, 2026, the cumulative number of multi-specialty procedures performed with the SSi Mantra reached 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Approximately 2,100 physicians have been trained on the system, which has been used for over 170 different types of procedures. This growing procedure volume and physician training underscore the platform's versatility and acceptance in the medical community.
The company continues to pursue regulatory clearance in both the United States and Europe, while expanding its presence in emerging healthcare markets. The strong first-quarter results and ongoing international expansion suggest that SS Innovations is well-positioned to capture a larger share of the global surgical robotics market, which is expected to grow significantly in the coming years. For more information, visit the company's website at www.SSInnovations.com.
This news matters because it demonstrates the viability of surgical robotics in diverse healthcare settings, potentially lowering barriers to advanced surgical care in developing countries. The successful telesurgery also points to a future where geographic distance is less of a limitation for patients needing specialized procedures. As SS Innovations gains regulatory approvals in more countries, the implications for global health equity and surgical outcomes could be substantial.
